The Centers for Medicare & Medicaid Services began its GLP-1 Bridge demonstration program on July 1, giving eligible Medicare Part D beneficiaries access to certain weight-loss medications for a capped monthly cost of $50, running through December 31, 2027.
Under federal law, Medicare Part D plans generally cannot cover medications prescribed specifically for weight loss, a restriction that has limited access to popular GLP-1 drugs for beneficiaries seeking treatment for obesity rather than diabetes. The Bridge program is designed as a temporary workaround, operating under CMS's authority to test new care-delivery approaches, rather than a permanent change to Part D coverage rules.
CMS Administrator Dr. Mehmet Oz framed the move as an access initiative, saying the demonstration was intended to make "a major medical advancement" affordable for seniors previously priced out. A related, broader coverage model originally planned to begin in January 2027 has been delayed indefinitely, with the Bridge program extended in its place through the end of 2027.
A separate Gallup survey released the same week found that 11% of U.S. adults currently take a GLP-1 medication for weight loss, up sharply from 3% in 2024, alongside a decline in the national obesity rate to 36.4% from a 2022 peak of 39.9%.
For anyone starting or adjusting a GLP-1 treatment plan, expectations around long-term weight maintenance still matter regardless of coverage costs -- our Weight Loss Reality Simulator models realistic maintenance-phase regain risk using published research on post-treatment weight trajectories.
Sources: CMS.gov, Medicare Rights Center